Short answer
Tango Therapeutics, Inc. (TNGX) filed an 8-K current report with the SEC on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Press release covers Tango Therapeutics’ quarter ended September 30, 2026.
Tango Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Press release covers Tango Therapeutics’ quarter ended September 30, 2026
- Exhibit 99.1 contains the company’s operating results and financial condition update
Item EX-99.1 · Exhibit EX-99.1
- Phase 1/2 combination data showed 82% ORR and 88% nine-month PFS in 2L/3L pancreatic cancer
- Phase 3 front-line MTAP-deleted pancreatic cancer study planned for 1H 2027, with ORR and PFS as primary endpoints
- Cash, cash equivalents and marketable securities totaled $977.5M, supporting the current operating plan
- Collaboration revenue fell to $0 from $53.8M year over year, reflecting completion of the Gilead collaboration
- Nine-month net loss widened to $169.2M, or $1.08 per share, from $62.8M, or $0.57 per share
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Tango Therapeutics, Inc. 8-K filings
Get the next TNGX 8-K as it lands
Follow TNGX for push alerts, or ask the research agent what this filing means.